If you are not happy with the results, please do another search

JSA Advises ELIQUENT Life Sciences and GHO Capital on its acquisition of 100% stake in Truliant Consulting

JSA advised ELIQUENT Life Sciences and GHO Capital on its 100% acquisition of Truliant Consulting Private Limited, as part of the global acquisition of its group company, Truliant Consulting LLC. ELIQUENT Life Sciences is a leading global consulting group delivering regulatory affairs, pharmacovigilance, quality and compliance solutions that support clients across therapeutic modalities, phase-based pathways and major global markets.

The integration of Truliant’s specialized knowledge and technology-driven service offerings expands ELIQUENT’s pharmacovigilance platform.

JSA assisted in all aspects of the transaction at the India level including structuring, negotiating, drafting and finalizing the definitive agreements.

The transaction team comprised of Lead Partner, Anand Lakra, Partner, Niharika Mepani, Principal Associate, Ami Shah, Associates, Rishabh Sharma, Diya Daveand Ishan Saxena.

Our employment team comprised of Partner, Sonakshi Das and Associate, Ananya Sharma.

Our taxation team comprised of Partner and Head of Practice, Direct Tax Kumarmanglam Vijay, Partner, Surajkumar Shetty and Associate, Tejasvi Shukla.

Media CoverageBusinesswire

ASG Hospital Private Limited acquires controlling stake in Prism Eye Institute Private Limited

JSA advised and assisted ASG Hospital Private Limited (ASG), a leading chain of super specialty eye hospitals and clinics in India, in connection with its acquisition in Prism Eye Institute Private Limited (Prism Institute), with a right to purchase remaining stake as per the transaction documents.

Prism Institute is a super specialty eye care hospitals based out of Mumbai, Maharashtra.

The deal involved transfer of business of eye care hospital manged by Prism Eye Institute and Research Center LLP to Prism Institute and subsequent acquisition of majority stake in Prism Institute by ASG. JSA’s assisted in advising on structuring of the transaction, due diligence, preparation, negotiation and finalization of transaction documents.

Our transaction team comprised: Partner – Rajul Bohra, Senior Associate – Priyal Jain Somvanshi, and Associate – Ishani Moulik.

Exit of Affirma Capital from Tirupati Medicare Limited.

JSA advised TBO Korea Holdings Limited and Augusta Investments Zero Pte. Ltd. (collectively, “Affirma Capital“) in the sale of its minority stake in Tirupati MedicareLimited (“Target”) to Kotak Strategic Situations Fund II and Kotak Alternate Asset Managers Limited (collectively, “Buyers”) for a consideration of (approximately) INR 1050 Crore.

The deal also involved infusion of capital by the Buyers in lieu of debentures issued by the Target, and acquisition of shares by the Buyers from the promoters of the Target. The Target (along with its group companies) is in the business of contract manufacturing and production of pharmaceutical, nutraceuticals, ayurvedic products.

JSA had previously advised Affirma Capital (previously, Standard Chartered Private Equity Managers Korea Limited) in its acquisition of shares of the Target.

Deal Value – USD 122.6 Million

Signing Date – 12th February 2025.

Media CoverageThe Economic Times

Chemfield Cellulose’s stake sale to Oji Holdings Corporation

JSA advised Chemfield Cellulose Private Limited (CCPL) and its Promoters on the divestment of a strategic stake in CCPL to Oji Holdings Corporation. The transaction is proposed to be undertaken in multiple tranches and is subject to receipt of regulatory approvals.

CCPL is India’s first and leading manufacturer of high-quality and consistent Microcrystalline Cellulose for the pharmaceutical industry.

This transaction was led by Partner – Vikram Raghani with support from Partners – Abhijeet Sonawane and Birbahadur Sachar, Principal Associate – Vwastav Ghosh, and Associates – Nishi Shah and Tavishi Chandra.

JSA advised ASG Hospital on its acquisition of Vission Eye Hospital

JSA advised ASG Hospital on its acquisition of Vission Eye Hospital, set up by Dr. Himanshu Mehta, a leading ophthalmologist.

Our transaction team comprised: Lead Partner – Siddharth Mody, Partner – Rohan Kumar, and Senior Associate – Alister Sequeira.

Our due diligence team comprised: Principal Associate – Prerana Chaudhari, Senior Associate – Alister Sequeira, and Associate – Ayush Chaturvedi.

ASG Hospital’s acquisition of a majority stake in Vedanta Centre for Ophthalmic Sciences

JSA advised and assisted ASG Hospital Private Limited (ASG) in acquiring a majority stake in Vedanta Centre for Ophthalmic Science Private Limited. Vedanta Centre for Ophthalmic Science Private Limited is a leading eye hospital in Patna.

The deal involved transferring the eye care hospital to an entity acquired by ASG. JSA assisted in advising on the transaction’s structuring, due diligence, preparation, negotiation, and finalization of transaction documents.

Our transaction team comprised: Partner – Rajul Bohra, Principal Associate – Priyal Jain Somvanshi, and Associates – Anmol Khurana and Ishani Moulik.

JSA advises Promoters of Mega Fine Pharma Private Limited on acquisition of majority stake by Motilal Oswal

JSA advised Mr. Shailesh Sanghvi (Promoter and Managing Director) and other continuing Promoter shareholders of the Sanghvi family in relation to a transaction involving acquisition of majority stake of Mega Fine by MO Alternate Investment Advisors Private Limited, a subsidiary of Motilal Oswal Financial Services Limited. Shailesh Sanghvi and family will continue as Promoters of Mega Fine.

Mega Fine is a Mumbai based export focused company engaged in development, manufacturing, and sale of a diverse range of high-value, low-volume niche for chronic therapies active pharmaceutical ingredients (APl). It has two USFDA approved manufacturing facilities in Nashik and Vapi. Mega Fine has long-standing relations with leading global pharmaceutical companies and has achieved global market leadership in some of its key APls.

Our transaction team comprised: Lead Partner – Vikram Raghani, Partner – Abhijeet Sonawane, and Associates – Vaishnavi Vyas and Tanishqua Desai.

JSA advised Health Catalyst on the India leg of its acquisition of Upfront Healthcare Services

JSA advised Health Catalyst (Nasdaq: HCAT) on the India leg of its acquisition of Upfront Healthcare Services, a health-tech provider with a next-generation patient engagement platform.

Health Catalyst is a leading technology and services company based in the United States. More than 1,000 organizations worldwide rely on Health Catalyst’s offerings, including its cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records.

This deal will enable Health Catalyst to combine Upfront Healthcare Services’ patient acquisition and scheduling expertise with Health Catalyst’s robust patient engagement portfolio. JSA’s M&A expertise (particularly in relation to technology & healthcare companies) along with past experience assisting Health Catalyst with numerous India-level acquisitions – were each key factors enabling a timely and smooth transaction, achieving Health Catalyst’s objectives for the deal.

Our transaction team comprised, Lead Partner – Probir Roy Chowdhury, Partner – Yajas Setlur, and Associates – Nikhil George and Moushami Nayak.